66.07 +0.21 (0.32%)
After hours: 4:25PM EDT
|Bid||65.02 x 2200|
|Ask||65.85 x 2200|
|Day's Range||65.67 - 66.58|
|52 Week Range||60.32 - 72.90|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||14.27|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||2.52 (3.86%)|
|1y Target Est||79.97|
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
The typical Facebook employee stays with the company for just over 2.5 years, a Business Journal analysis shows. This is how that compares to other large Silicon Valley tech employers, like Cisco, Apple and Intel.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
Gilead corporate development head Andy Dickinson’s elevation to CFO means that partnerships and acquisitions will be at the center of the company’s strategy, one analyst says.
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
Gilead Sciences Inc. said Tuesday it has appointed Andrew Dickinson as chief financial officer, effective Nov. 1. Dickinson is currently executive vice president corporate development and strategy and will become a member of the senior leadership team reporting to Chief Executive Daniel O'Day. The executive joined the company in 2016 after stints at Lazard and Myogen Inc., which Gilead acquired in 20016. Shares were not yet active premarket, but have gained 3% in 2019, while the S&P 500 has gained 18%.
Gilead Sciences, Inc. (GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1. Mr. Dickinson currently serves as the company’s Executive Vice President, Corporate Development and Strategy, and in his new role he will continue to be a member of the senior leadership team, reporting to Daniel O’Day, Chairman and Chief Executive Officer. Mr. Dickinson joined Gilead in 2016 and has transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making.
South San Francisco-based Allogene is taking a different approach to cell therapy for cancer by producing so-called allogenic cell therapies.
A biotech company that started in Israel 21 months ago and moved to San Francisco this year wants to raise $70 million through an initial public offering to tackle one of the hottest areas of drug development. Fourteen-employee 89bio Inc. stated in a Securities and Exchange Commission filing Friday that it plans to use the cash to complete mid-stage clinical trials of its signature drug against the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, and severe hypertriglyceridemia as well as for drug manufacturing. NASH has attracted deep-pocketed drug companies such as Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), South San Francisco's NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Pfizer Inc. (NYSE: PFE) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) and an army of smaller companies, such as South San Francisco's Akero Therapeutics Inc. (NASDAQ: AKRO).
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...